SCHEMBL545367

SCHEMBL545367

O=[N+]([O-])c1cc(CO)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
HIF1A Q16665 1/20 0.56
VCAM1 P19320 1/20 0.53
MAPT P10636 3/20 0.50
LMNA P02545 6/20 0.49
RECQL P46063 1/20 0.49
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
HTT P42858 3/20 0.45
CA1 P00915 1/20 0.45
MMP2 P08253 1/20 0.45
CA14 Q9ULX7 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
TTR P02766 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29990481 1.00 ALDH1A1 (0.56) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL2340873 0.86 ALDH1A1 (0.53) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL29988362 0.86 ALDH1A1 (0.53) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL571701 0.85 ATM (0.58) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL14880650 0.85 ALDH1A1 (0.60) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL3120356 0.83 ALDH1A1 (0.58) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL515466 0.82 MAPT (0.54) ALDH1A1MAPTSMN1; SMN2ATMTDP1
SCHEMBL28563347 0.82 GAA (0.49) ALDH1A1MAPTLMNARECQLMEN1
SCHEMBL31023151 0.81 ALDH1A1 (0.56) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL960995 0.81 ALDH1A1 (0.56) ALDH1A1HIF1AVCAM1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3547414-B1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
EP-3664213-B1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
US-11495824-B2 Electrolyte for lithium metal battery and lithium metal battery comprising same LG ENERGY SOLUTION, LTD. (KR) 2022-11-08 US claimed
CN-110192294-B Lithium electrode and lithium secondary battery comprising same 株式会社LG新能源 2022-09-20 CN claimed
CN-111033864-B Electrolyte for lithium metal battery and lithium metal battery comprising same 株式会社LG新能源 2022-08-12 CN claimed
US-20200203759-A1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2020-06-25 US claimed
EP-3664213-A2 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2020-06-10 EP claimed
US-20190319272-A1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2019-10-17 US claimed
EP-3547414-A2 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2019-10-02 EP claimed
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 EP disclosed
US-12466815-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2025-11-11 US disclosed
EP-4613752-A1 POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2025-09-10 EP disclosed
US-20250276977-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2025-09-04 US disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 US disclosed
WO-2001098282-A1 BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD (JP) 2001-12-27 WO disclosed
CN-1021283-C HERBICIDES SHELL INT RESEARCH (NL) 1993-06-23 CN disclosed
EP-0260744-B1 (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1992-12-16 EP disclosed
US-4859684-A (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders JANSSEN PHARMACEUTICA N.V. (BE) 1989-08-22 US disclosed
EP-0260744-A2 (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1988-03-23 EP disclosed
CN-86107990-A Herbicide 1987-07-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276977-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 ALDH1A1 4098/4885HIF1A 2851/4885VCAM1 1439/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ALDH1A1 1136/4885HIF1A 1812/4885VCAM1 574/4885
US-12466815-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 ALDH1A1 2561/4885HIF1A 612/4885VCAM1 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.